[Permeation of active morphine-like substances at their sites of antinociceptive action in the brain as a function of their lipid-solubility following intravenous and intraventricular application].
D000818:Animals; D001921:Brain / Q000378:metabolism*; D002247:Carbon Isotopes; D002855:Chromatography, Thin Layer; D003061:Codeine / Q000378:metabolism*; D003791:Dental Pulp Test; D005283:Fentanyl / Q000378:metabolism*; D004091:Hydromorphone / Q000378:metabolism*; D007659:Ketones / Q000378:metabolism*; D007700:Kinetics; D007981:Levorphanol / Q000378:metabolism*; D008055:Lipids; D008691:Methadone / Q000378:metabolism*; D009019:Morphinans / Q000378:metabolism*; D009020:Morphine / Q000378:metabolism*; D010880:Piperidines / Q000378:metabolism*; D011817:Rabbits; D012995:Solubility; D014316:Tritium
D002247:Carbon Isotopes; D007659:Ketones; D008055:Lipids; D009019:Morphinans; D010880:Piperidines; D014316:Tritium; D007981:Levorphanol; D009020:Morphine; D004091:Hydromorphone; D008691:Methadone; D005283:Fentanyl; D003061:Codeine
Permeation morphinartig wirksamer Substanzen an den Ort der antinociceptiven Wirkung im Gehirn in Abhängigkeit von ihrer Lipoidlöslichkeit nach intravenöser und nach intraventrikulärer Applikation.